6 July 2022 – Moderna Switzerland GmbH has submitted an application to Swissmedic to extend the authorisation for its Covid-19 vaccine Spikevax®, which was originally authorised in January 2021. The bivalent vaccine contains messenger ribonucleic acid (mRNA) both for the spike protein of the Wuhan strain and for that of the Omicron variant. The modified composition promises to be more effective against the Omicron variant of the SARS-CoV-2 coronavirus.

For more information, see here.